HIV Infection

• PO (Adults): 100 mg every 4 hr while awake or 200 mg 3 times daily or 300 mg twice daily (depends on combination and clinical situation).
• PO (Children 4 wk–<18 yr): 4–8.9 kg: 12 mg/kg twice daily or 8 mg/kg 3 times daily; 9–29.9 kg: 9 mg/kg twice daily or 6 mg/kg 3 times daily; ≥30 kg: 300 mg twice daily or 200 mg 3 times daily.
• IV (Adults and Children >12 yr): 1 mg/kg every 4 hr. Change to oral therapy as soon as possible.
• IV (Children): 120 mg/m² every 6 hr (not to exceed 160 mg/dose) or 20 mg/m²/hr as a continuous infusion.

Prevention of Maternal/Fetal Transmission of HIV Infection

• PO (Adults >14 wk Pregnant): 100 mg 5 times daily until onset of labor.
• IV (Adults during Labor and Delivery): 2 mg/kg over 1 hr, then continuous infusion of 1 mg/kg/hr until umbilical cord is clamped.
• PO (Neonates): 2 mg/kg every 6 hr until 6 wk of age.
• IV (Neonates): 1.5 mg/kg every 6 hr until 6 wk of age.

Retrovir

• Following intracellular conversion to its active form, inhibits viral RNA synthesis by inhibiting the enzyme DNA polymerase (reverse transcriptase).
• Prevents viral replication.

• Virustatic action against selected retroviruses.
• Slowed progression and decreased sequelae of HIV infection.
• Decreased viral load and improved CD4 cell counts.
• Decreased transmission of HIV to infants born to HIV-infected mothers.

Therapeutic Classification: antiretrovirals

Pharmacologic Classification: nucleoside reverse transcriptase inhibitors

Absorption: Well absorbed following oral administration.

Distribution: Widely distributed; enters the CNS.

Metabolism/Excretion: Mostly (75%) metabolized by the liver; 15–20% excreted unchanged by the kidneys.

Half-life: 1 hr.

(plasma concentrations)

• Instruct patient to take zidovudine as directed, around the clock, even if sleep is interrupted. Emphasize the importance of compliance with therapy, not taking more than prescribed amount, and not discontinuing without consulting health care professional. Take missed doses as soon as remembered unless almost time for next dose; do not double doses. Inform patient that long-term effects of zidovudine are unknown at this time.
• Instruct patient that zidovudine should not be shared with others.
• Zidovudine may cause dizziness or fainting. Caution patient to avoid driving or other activities requiring alertness until response to medication is known.
• Inform patient that zidovudine does not cure HIV and may reduce the risk of transmission of HIV to others through sexual contact or blood contamination. Caution patient to use a condom during sexual contact and avoid sharing needles or donating blood to prevent spreading the AIDS virus to others.
• Instruct patient to notify health care professional promptly if signs of pancreatitis (nausea, vomiting, abdominal pain), lactic acidosis (feel very weak or tired; feel cold, especially in arms and legs; unusual muscle pain; feel dizzy or lightheaded; trouble breathing; fast or irregular heartbeat; stomach pain with nausea and vomiting), liver problems (yellowing of skin or white part of eyes; loss of appetite; nausea; dark or "tea-colored" urine; pain, aching, or tenderness on right side of abdomen; light-colored stools) or immune reconstitution syndrome (signs and symptoms of an infection, Mycobacterium avium infection, cytomegalovirus, Pneumocystis jirovecii pneumonia, tuberculosis) occur.
• Instruct patient to notify health care professional promptly if fever, sore throat, signs of infection, muscle weakness, or shortness of breath occurs. Caution patient to avoid crowds and persons with known infections. Instruct patient to use soft toothbrush, to use caution when using toothpicks or dental floss, and to have dental work done prior to therapy or deferred until blood counts return to normal.
• Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
• Inform patient that redistribution and accumulation of body fat may occur, causing central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, breast enlargement, and cushingoid appearance. The cause and long-term effects are not known.
• Rep: Advise females of reproductive potential to notify health care professional if pregnancy is planned or suspected and avoid breastfeeding. Advise patient taking oral contraceptives to use a nonhormonal method of birth control during therapy. Inform patient of pregnancy exposure registry that monitors pregnancy outcomes in women exposed to zidovudine during pregnancy. Enroll patients in the Antiretroviral Pregnancy Registry by calling 1-800-258-4263.
• Emphasize the importance of regular follow-up exams and blood counts to determine progress and monitor for side effects.

zye-DOE-vue-deen

NDC Code^*

• 0378- Mylan Pharmaceuticals Inc.
  • 0378-6106- Zidovudine
    • 0378-6106-91- 60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0378-6106-91)

• 0527- Lannett Company, Inc.
  • 0527-1905- Zidovudine
    • 0527-1905-06- 60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0527-1905-06)

• 31722- Camber Pharmaceuticals, Inc.
  • 31722-509- Zidovudine
    • 31722-509-60- 12 BOTTLE in 1 CASE (31722-509-60) > 60 TABLET in 1 BOTTLE

• 49702- ViiV Healthcare Company
  • 49702-211- RETROVIR
    • 49702-211-20- 100 CAPSULE in 1 BOTTLE (49702-211-20)

• 49702- ViiV Healthcare Company
  • 49702-212- RETROVIR
    • 49702-212-48- 240 mL in 1 BOTTLE (49702-212-48)

• 49702- ViiV Healthcare Company
  • 49702-213- RETROVIR
    • 49702-213-26- 5 VIAL, SINGLE-USE in 1 CARTON (49702-213-26) > 20 mL in 1 VIAL, SINGLE-USE (49702-213-01)

• 52343- ACETRIS HEALTH, LLC
  • 52343-044- Zidovudine
    • 52343-044-01- 100 CAPSULE in 1 BOTTLE (52343-044-01)

• 52343- ACETRIS HEALTH, LLC
  • 52343-045- Zidovudine
    • 52343-045-60- 60 TABLET, FILM COATED in 1 BOTTLE (52343-045-60)

• 53104- Cipla Ltd.
  • 53104-0100- Zidovudine
    • 53104-0100-4- 100 CAPSULE in 1 BOTTLE (53104-0100-4)

• 53104- Cipla Ltd.
  • 53104-0100- Zidovudine
    • 53104-0100-6- 1000 CAPSULE in 1 BOTTLE (53104-0100-6)

• 53104- Cipla Ltd.
  • 53104-0101- Zidovudine
    • 53104-0101-2- 60 TABLET, FILM COATED in 1 BOTTLE (53104-0101-2)

• 53104- Cipla Ltd.
  • 53104-0101- Zidovudine
    • 53104-0101-6- 1000 TABLET, FILM COATED in 1 BOTTLE (53104-0101-6)

• 53104- Cipla Ltd.
  • 53104-0101- Zidovudine
    • 53104-0101-9- 100 TABLET, FILM COATED in 1 BOX, UNIT-DOSE (53104-0101-9)

• 53104- Cipla Ltd.
  • 53104-0105- zidovudine
    • 53104-0105-9- 240 mL in 1 BOTTLE (53104-0105-9)

• 53808- DOH CENTRAL PHARMACY
  • 53808-0812- Zidovudine
    • 53808-0812-1- 30 TABLET, FILM COATED in 1 BLISTER PACK (53808-0812-1)

• 53808- State of Florida DOH Central Pharmacy
  • 53808-0878- Zidovudine
    • 53808-0878-2- 60 TABLET, FILM COATED in 1 BLISTER PACK (53808-0878-2)

• 65862- Aurobindo Pharma Limited
  • 65862-024- Zidovudine
    • 65862-024-10- 6 BLISTER PACK in 1 CARTON (65862-024-10) > 10 TABLET, FILM COATED in 1 BLISTER PACK

• 65862- Aurobindo Pharma Limited
  • 65862-024- Zidovudine
    • 65862-024-60- 60 TABLET, FILM COATED in 1 BOTTLE (65862-024-60)

• 65862- Aurobindo Pharma Limited
  • 65862-048- Zidovudine
    • 65862-048-24- 240 mL in 1 BOTTLE (65862-048-24)

• 65862- Aurobindo Pharma Limited
  • 65862-107- Zidovudine
    • 65862-107-01- 100 CAPSULE in 1 BOTTLE (65862-107-01)

• 65862- Aurobindo Pharma Limited
  • 65862-107- Zidovudine
    • 65862-107-10- 10 BLISTER PACK in 1 CARTON (65862-107-10) > 10 CAPSULE in 1 BLISTER PACK

• 70518- REMEDYREPACK INC.
  • 70518-1656- Zidovudine
    • 70518-1656-0- 30 TABLET in 1 BLISTER PACK (70518-1656-0)